PeptidePedia The community reference

Contributions of IcodecIndra

User contributions·25 logged edits·page 1 of 1

Contributions by IcodecIndra, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,088 edits includes activity predating the current log.

  1. 08:55, 19 May 2026 (diff | hist) International nonproprietary name 4,356 ±0 correct the dose ladder — the maintenance dose is not the maximum dose
  2. 19:52, 1 Apr 2026 (diff | hist) Glucagon 7,074 ±0 serial comma per PP:MOS
  3. 21:32, 4 Oct 2025 (diff | hist) Peptide 6,813 ±0 m copyedit
  4. 23:04, 14 Sep 2025 (diff | hist) Lyophilisation 27,583 +1,208 add the cross-link to the temperature-excursion article
  5. 15:23, 2 Aug 2025 (diff | hist) Contract development and manufacturing organisation 4,794 ±0 correct the humidity figure — relative humidity needs its temperature
  6. 09:57, 2 Aug 2025 (diff | hist) Survodutide 5,302 +774 add the receptor targets to the lead sentence
  7. 06:39, 19 Jul 2025 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 add category for the drug class
  8. 21:36, 25 Jun 2025 (diff | hist) Amylin receptor agonist 4,965 +1,038 split §Pharmacology into receptor binding and downstream signalling
  9. 05:03, 17 Jun 2025 (diff | hist) Semaglutide 8,560 ±0 correct the molar mass — source gives the free-base figure, we had the salt
  10. 14:50, 15 Jun 2025 (diff | hist) GLP-1 receptor agonist 9,758 ±0 serial comma per PP:MOS
  11. 07:03, 3 Jun 2025 (diff | hist) Amylin 4,277 +25 add see also to the amylin analogue
  12. 18:49, 4 Mar 2025 (diff | hist) Liraglutide 4,532 +237 close an unbalanced quotation mark
  13. 15:09, 23 Feb 2025 (diff | hist) Cagrilintide 3,187 +40 split §Pharmacology into receptor binding and downstream signalling
  14. 07:22, 8 Feb 2025 (diff | hist) Tirzepatide 6,234 +845 expand §Adverse effects and tolerability
  15. 00:35, 11 Jan 2025 (diff | hist) Dual incretin agonist 4,587 +16 m add a hatnote pointing at the analogue with the similar name
  16. 19:47, 1 Dec 2024 (diff | hist) Survodutide 2,514 ±0 attribute the mechanism claim to the review rather than stating it flatly
  17. 14:15, 1 Dec 2024 (diff | hist) ChinaPeptides 3,956 ±0 m add category for suppliers in China
  18. 11:56, 20 Nov 2024 (diff | hist) Survodutide 2,514 +1,058 state the substitution in one-letter code as well, per PP:MOS
  19. 16:23, 20 Oct 2024 (diff | hist) Amylin 3,204 +639 m convert the substitution list to a table so the analogues line up
  20. 02:48, 12 Oct 2024 (diff | hist) Test report forgery 1,322 ±0 m fix a dangling clause
  21. 02:12, 23 Sep 2024 (diff | hist) Cagrilintide 2,102 +215 correct the dose ladder — the maintenance dose is not the maximum dose
  22. 00:36, 1 Sep 2024 (diff | hist) Oral semaglutide 1,429 +1,429 N new article: compound, expansion welcome
  23. 07:41, 27 Aug 2024 (diff | hist) Liraglutide 2,493 ±0 add the year of first marketing authorisation, with the regulator named
  24. 09:00, 13 Aug 2024 (diff | hist) Cagrilintide 1,293 +1,293 N new article: compound, expansion welcome
  25. 03:37, 2 Jul 2024 (diff | hist) Tirzepatide 2,181 ±0 m expand §Adverse effects and tolerability